Roche said the new Elecsys Anti-p53 immunoassay uses the electrochemiluminescence immunoassay ECLIA technology and is intended for use on cobas e immunoassay analyzers. It is a high precision ...

The new Elecsys Anti-p53 immunoassay uses the well-established electrochemiluminescence immunoassay “ECLIA” technology and is intended for use on cobas e immunoassay analyzers.

Alternatively, they performed the electrochemiluminescence immunoassay (ECLIA) to detect IgG, IgA, and IgM levels in the sera against the S receptor-binding (RBD) domain. Here, a cut-off index ≥ ...

The Elecsys IL-6 immunoassay is an electrochemiluminescence immunoassay “ECLIA” and is intended for use on cobas e immunoassay analyzers. Founded in 1896 in Basel, Switzerland, as one of the first ...

June 2, 2010 — The US Food and Drug Administration (FDA) has granted premarket approval for an electrochemiluminescence immunoassay (Elecsys Anti-HCV; Roche Diagnostics Corp) for the qualitative ...

(RTTNews) - The U.S. Food and Drug Administration has granted breakthrough device designation for Roche's (RHHBY) Elecsys growth differentiation factor-15 or GDF-15 assay to help identify patients ...

The University of Kansas in collaboration with PerkinElmer Inc. worked on looking at the comparison of the AlphaLISA Technology and an Electrochemiluminescence Technology to measure assay windows, ...

The new Elecsys Anti-p53 immunoassay uses the well-established electrochemiluminescence immunoassay “ECLIA” technology and is intended for use on cobas e immunoassay analyzers. For further information ...